A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 09, 2025
Terminated
Keywords
ClinConnect Summary
Dendritic cells are a type of white blood cell used by the body to fight infection. They are instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic cells from an HIV-negative sibling may enable the affected sibling's immune system to recognize foreign particles more readily and increase immune response against the virus.
Dendritic cells from an HIV-negative sibling are obtained and treated with various viral proteins (HIV vaccines) or immunomodulators. The tr...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HLA A2+.
- • Same cell type as donor sibling.
- • CD4 count \> 350 cells/mm3.
- • HIV asymptomatic status.
- • No HIV antivirals during study.
- • Normal labs and chest x-ray.
- Donor siblings must have:
- • HLA A2+.
- • HIV negativity.
- • Ability to donate cells on multiple occasions.
- • Negative status for hepatitis B and C.
- • Exclusion Criteria
- Concurrent Medication:
- Excluded:
- • Antiviral therapy (unless CD4 count declines to \< 350 cells/mm3).
- Prior Medication:
- Excluded:
- • Antiviral therapy within 90 days prior to study entry.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials